Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP & General Counsel | November 17, 2025 | November 19, 2025 |
| MiniMed Group, Inc.MMED · Entity 3758 | SVP, Gen. Counsel & Corp. Sec. | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,847 |
Reported balance
After 2025-11-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-11-17 · Exercise / conversion · Acquired 278 · Balance 26,847 |
| Common StockSEC Table I · non-derivative | Direct | 26,569 |
Reported balance
After 2025-11-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-11-17 · Sale · Disposed 278 · Balance 26,569 F1: This includes an aggregate of 25,913 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.25 · Expires 2034-07-14 | Direct | 8,883 |
Reported balance
After 2025-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-17 · Exercise / conversion · Disposed 278 · Balance 8,883 F2: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: This includes an aggregate of 25,913 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.
F2: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
MiniMed Group, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,939 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 58,939 · Balance 58,939 F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date. F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date.
F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2024 Filed Jul 17, 2024 16:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 13,323 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0000879169-24-000136 · wk-form4_1721233758.xml · derivative · entry 2 Denton Sheila A. · CIK 0001995298 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,323 Underlying: Common Stock · 13,323 shares Expires 2034-07-14 F3 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 5,955 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000136 · wk-form4_1721233758.xml · nonDerivative · entry 1 Denton Sheila A. · CIK 0001995298 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,479 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 32,479 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 19:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 28,725 | $0.00 Strike: $58.06 | $0.00 |
DisclosureSEC source: 0000879169-23-000033 · wk-form4_1696446492.xml · derivative · entry 2 Denton Sheila A. · CIK 0001995298 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,725 Underlying: Common Stock · 28,725 shares Expires 2033-10-02 F3 · derivative.exercise_date: The October 2, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 19:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 26,524 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-23-000033 · wk-form4_1696446492.xml · nonDerivative · entry 1 Denton Sheila A. · CIK 0001995298 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,524 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the October 2, 2023 RSU Grant, this includes an aggregate of 26,524 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.